Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-15
2005-02-15
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S269000, C514S274000, C514S275000, C544S315000, C544S316000, C544S318000, C544S331000, C544S332000, C544S333000, C544S335000
Reexamination Certificate
active
06855716
ABSTRACT:
Dihydropyrimidine derivatives of the following formula or analogs thereof have selective N-type calcium channel antagonistic activity, and they are used as therapeutic agents for various diseases participating in the N-type calcium channels.
REFERENCES:
patent: 4675321 (1987-06-01), Baldwin et al.
patent: 5767129 (1998-06-01), Yuen
patent: 6172066 (2001-01-01), Nagarathnam et al.
patent: 6320049 (2001-11-01), Sidler et al.
patent: 6339696 (2002-01-01), Chan et al.
patent: 6350762 (2002-02-01), Niwa et al.
patent: 6350766 (2002-02-01), Uneyama et al.
patent: 6436943 (2002-08-01), Stoltefuss et al.
patent: 0 237 347 (1987-09-01), None
patent: WO 9313128 (1993-07-01), None
patent: WO 9614846 (1996-05-01), None
patent: WO 9717969 (1997-05-01), None
patent: WO 9742956 (1997-11-01), None
patent: WO 9849144 (1998-05-01), None
patent: WO 9851311 (1998-11-01), None
patent: WO 9901437 (1999-01-01), None
patent: WO 9901438 (1999-01-01), None
patent: WO9932446 (1999-07-01), None
patent: WO 9932446 (1999-07-01), None
patent: WO 9954312 (1999-10-01), None
patent: WO 9954326 (1999-10-01), None
patent: WO 9954329 (1999-10-01), None
Oliver P. Kleidernigg, et al., Separation of Enantiomers of 4-Aryldihydropyrimidines by Direct Enantioselective HPLC. A Critical Comparison of Chiral Stationary Phases; Institute of Organic Chemistry, Karl-Franzens-university Graz, Heinrichstrasse 28, A-8010 Graz, Austria; Tetrahedron: Asymmetry, vol. 8, No. 12, pp. 2057-2067, 1997.
Brian Cox, et al.; Monthly Focus: Central & Peripheral Nervous Sytems, N-Type Calcium Channel Blockers in Pain and Stroke; Glaxo Wellcome, Medicinal Sciences & Lead Discovery, Medicines Research Centre, Gunneis Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK; Exp. Opin. Ther. Patents (1998) 8(10): pp. 1237-1250.
Dodd, et al.; Excitotoxic Mechanisms in the Pathogenesis of Dementia; Clinical Research Laboratory, Royal Brisbane Hospital Foundation, Australia; Neurochem Int Sep. 25, 1994 (3): pp. 203-219 (Abstract only).
Atsushi Kuno et al., “Studies on Cerebral Protective Agents. II. Novel 4-Arylpyrimidine Derivatives with Anti-Anoxic and Anti-Lipid Peroxidation Activities,”Chem. Pharm. Bull. 40(9) 2423-2431 (1992).
Hitetsura Cho, et al., “Dihydropyrimidines: Novel Calcium Antagonists with Potent and Long-Lasting Vasodilative and Antihypertensive Activity,”J. Med. Chem., 1989, 32, 2399-2406.
YS Sadanandam et al., “Synthesis and Biological Evaluation of New 3,4-dihydro-6-methyl-5-N-methyl-carboamoyl-4-(substituted phenyl)-2-(1H)pyrimidinones and Pyrimidinethiones,”Eur J. Med. Chem., (1992) 27, 87-92.
Lange, et al.; Dopamine/Glutamate Interactions in Parkinson's Disease; Department of Neuropsychology and Behavioural Neurobiology, University of Freilburg, Germany; Neurosci Biobehav Rev Jul. 1997; 21(4): pp. 393-400 (Abstract only).
Kieburtz, et al.; Excitotoxicity and Dopaminergic Dysfunction in the Acquired Immunodeficiency Syndrome Dementia Complex, Therapeutic Implications; Department of Neurology, University of Rochester Medical Center, NY 14642; Arch Neurol Dec. 1991; 48(12): pp. 1281-1284 (Abstract only).
Imaizumi, et al.; The Role of Voltage-Gated Ca2+ Channels in Anoxic Injury of Spinal Cord White Matter; Department of Neurology, Yale University School of Medicine, New Haven, CT 06516, USA; Brain Res Jan. 30, 1999; 817(1-2): pp. 84-92 (Abstract only).
Madden, et al.; Treatment with Conotoxin, an ‘N-Type’ Calcium Channel Blocker, in Neuronal Hypoxicischemic Injury; Department of Neurosciences, University of California, San Diego 92161; Brain Res Dec. 24, 1990; 537(1-2): pp. 256-262 (Abstract only).
White, et al.; Effect of Subcutaneous Administration of Calcium Channel Blocker on Nerve Injury-Induced Hyperalgesia; Department of Anaesthesia and Pain Management, Royal North Shore Hospital, St. Leonards, N.S.W., 2065, Austrilia. dmwhite@med.usyd.edu.au; Brain Res Aug. 10, 1998; 801(1-2): pp. 50-58 (Abstract only).
Basilico, et al.; Influence of Omega-Conotoxin on Morphine Analgesia and Withdrawl Syndrome in Rats; Institute of Pharmacology, Faculty of Sciences, University of Milan, Italy; Eur J Pharmacol Jul. 21, 1992: 218(1): pp. 75-81 (Abstract only).
Pierce, et al.; Calcium-Mediated Second Messengers Modulate the Expression of Behavioral Sensitization to Cocaine; Department of Pharmacology and Psychiatry, Boston University School of Medicine, Boston, Massachusetts 02118-2394, USA; J Pharmacol Exp Ther Sep. 1998; 286(3): pp. 1171-1176 (Abstract only).
Monje et al, “A New Conus Peptide Ligand for Ca Channel Subtypes”, Neuropharmacology vol. 32, No. 11, pp. 1141-1149 (1993).
Uneyama et al., “Blockade of N-Type Ca2+Current by Cilnidipine (FRC-8653) in Acutely Dissociated Rat Sympathetic Neurones”, British Journal of Pharmacology, (1997) 122, 37-42.
Kajigaya Yuki
Kito Morikazu
Koganei Hajime
Niwa Seiji
Ohno Seiji
LandOfFree
Dihydropyrimidine compounds and compositions containing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydropyrimidine compounds and compositions containing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropyrimidine compounds and compositions containing the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3460687